Sep 2026· Journal of physiology and biochemistry· Vol 82· 0 citations· 142 references
Medicine
TL;DR
The gut microbiota–liver axis plays a central role in the pathogenesis of MASLD and emerging modalities within microbiome-based therapies, including mesenchymal stromal cell therapy and bacteriophage therapy, offer potential for targeted modulation of the gut microbiota and liver repair.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disorder worldwide, characterized by a multifactorial pathogenesis involving genetic predisposition, metabolic disturbances, environmental influences, and gut microbiota interactions. In recent years, the gu...
Wen-Xing Liu, Y.-Q. Lan, Xia Chen et al.· Frontiers in Microbiology· 0 citations
This narrative review explores the mechanistic pathways through which an altered gut microbiome contributes to MASLD, by specifically emphasizing intestinal barrier disruption, endotoxemia, altered bile acid metabolism, and SCFA imbalance.
Shweta Sharma, Arun Pachauri, Harsha Nagar et al.· Frontiers in Systems Biology· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed non-alcoholic fatty liver disease (NAFLD), affects a substantial proportion of the global adult population and is a leading cause of chronic liver disease. Its progression reflects interactions among metabolic dysfunction, genetic suscept...
E. Abady, Hazem AbuEl-Enien, Panos I. Tamvakologos et al.· Discover medicine· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) comprises a spectrum of liver diseases from simple steatosis to metabolic dysfunction-associated steatohepatitis and its associated fibrosis, cirrhosis, and MASLD-associated hepatocellular carcinoma (MASLD-HCC). MASLD affects over one-third of the global...
Huai Qian, Xiao-Lei Li, Hua Wang et al.· American Journal of Patholog...· 0 citations
Background: Non-alcoholic fatty liver disease (NAFLD), now largely encompassed by the metabolic dysfunction-associated steatotic liver disease (MASLD) framework, is a leading cause of chronic liver disease worldwide and is closely linked to obesity, insulin resistance, type 2 diabetes (T2D), and cardiometabolic dysfunc...
Marica Colella, Rossana Notaristefano, Maria Tragni et al.· Livers· 0 citations
Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly non-alcoholic fatty liver disease, is the most prevalent chronic liver disorder globally and is tightly linked to obesity, diabetes, dyslipidemia, and metabolic syndrome. MASLD spans a continuum from simple steatosis to metabolic dysfunction–ass...
Philippe Attieh, M. Nassif, Mark Maghzal et al.· Frontiers in Gastroenterolog...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
